Brief: Bioarctic Says Co & Eisai Announced Today That Leqembi Has Been Approved For Treatment Of Alzheimer's Disease In Israel
12/07/2024 24:31
July 11 (Reuters) - BioArctic AB BIOAb.ST :
* BIOARCTIC AB - CO & EISAI ANNOUNCED TODAY THAT LEQEMBI HAS
BEEN
APPROVED FOR TREATMENT OF ALZHEIMER'S DISEASE IN ISRAEL
Source text for Eikon: ID:nWkr8hYbDb
Further company coverage: BIOAb.ST
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln